{"id":519778,"date":"2021-07-29T07:36:03","date_gmt":"2021-07-29T11:36:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/"},"modified":"2021-07-29T07:36:03","modified_gmt":"2021-07-29T11:36:03","slug":"salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/","title":{"rendered":"Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results"},"content":{"rendered":"<h2>\nConference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">HOUSTON, July  29, 2021  (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematologic cancers, today announced that the Company will host a conference call and live audio webcast on\u00a0<strong>Thursday, August 5, 2021, at 10:00 a.m. ET<\/strong>, to discuss its corporate and financial results for the second quarter and year-to-date 2021.<\/p>\n<p align=\"justify\">\n        <strong>Conference Call Information<\/strong><\/p>\n<p>Interested participants and investors may access the conference call by dialing either:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">(833) 423-0481 (U.S.)<\/li>\n<li style=\"text-align:justify\">(918) 922-2375 (international)<\/li>\n<li style=\"text-align:justify\">Conference ID: 8985036<\/li>\n<\/ul>\n<p align=\"justify\">An audio webcast will be accessible via the Investors Events and Presentations section of the Company\u2019s website\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kvk-8UYUEEOIKYB4Lf_rSA5Uz9nOFtDaG0Bmw92woH7j4U8L-i3FJ5AsG0CrCPvcgwDZhqIT1DZ2LGwPazoNKRdHsmckkg-PEeQ2ECXi058gtr21awDbysrLKfoxrq1N\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/investors.salariuspharma.com\/<\/a>. An archive of the webcast will remain available for 90 days beginning at approximately\u00a011:00 a.m. ET, on\u00a0August 5, 2021.<\/p>\n<p align=\"justify\">\n        <strong>About Salarius Pharmaceuticals<\/strong><br \/>\n        <br \/>Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius\u2019 lead candidate, seclidemstat (or SP-2577), is being studied as a potential treatment for sarcomas, pediatric cancers, and other solid and hematologic cancers with limited treatment options. Seclidemstat is currently in a Phase 1\/2 clinical trial for sarcomas, including relapsed\/refractory Ewing sarcoma and additional select sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a Phase 1\/2 clinical study underway at MD Anderson Cancer Center in hematologic cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-5vmXDsDb5YBa5kzcgcE5ai9ef46xaICxCe7PwAcH5mQWeWJ6lIvq00f-TuIiEg_e5D_bMGZIZTe9D6a0jAPEoENSbkEcdIqWZzWX3gfZDM=\" rel=\"nofollow noopener\" target=\"_blank\">salariuspharma.com<\/a> or follow Salarius on Twitter and LinkedIn.<\/p>\n<p>\n        <strong>Contact<\/strong><br \/>\n        <br \/>Tiberend Strategic Advisors, Inc. <br \/>Maureen McEnroe, CFA<br \/>(212) 375-2664 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N0FWBYk2jmxn6acIL5WYrxHwbc9MDR2gJsf0Lw2Dqz0CKrtSAiccLD3gL6YIkWSp0txz1Ry-NJj85MOHSCJVZvCKjWvl4S3nJUB1477O7QY=\" rel=\"nofollow noopener\" target=\"_blank\">mmcenroe@tiberend.com<\/a><\/p>\n<p>Johanna Bennett (media relations)<br \/>(212)\u00a0375-2686\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mKzk9p_c2IuITuNisQs1dzpR35TtuqtjeEL86frOEYl4CNqHSyQUnOi-O_X7Al_6GQNRfODL3eqCaYIMHXb4tn2Fs6UvcoDq4bxJdABwqJA=\" rel=\"nofollow noopener\" target=\"_blank\">jbennett@tiberend.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODY3NyM0MzIwMjkxIzIwMTY3Nzc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/56dd21da-80de-488d-a706-8a8de99e2baf\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET HOUSTON, July 29, 2021 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematologic cancers, today announced that the Company will host a conference call and live audio webcast on\u00a0Thursday, August 5, 2021, at 10:00 a.m. ET, to discuss its corporate and financial results for the second quarter and year-to-date 2021. Conference Call Information Interested participants and investors may access the conference call by dialing either: (833) 423-0481 (U.S.) (918) 922-2375 (international) Conference ID: 8985036 An audio webcast will be accessible via the Investors Events and Presentations section &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-519778","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET HOUSTON, July 29, 2021 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematologic cancers, today announced that the Company will host a conference call and live audio webcast on\u00a0Thursday, August 5, 2021, at 10:00 a.m. ET, to discuss its corporate and financial results for the second quarter and year-to-date 2021. Conference Call Information Interested participants and investors may access the conference call by dialing either: (833) 423-0481 (U.S.) (918) 922-2375 (international) Conference ID: 8985036 An audio webcast will be accessible via the Investors Events and Presentations section &hellip; Continue reading &quot;Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T11:36:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODY3NyM0MzIwMjkxIzIwMTY3Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results\",\"datePublished\":\"2021-07-29T11:36:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/\"},\"wordCount\":355,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODY3NyM0MzIwMjkxIzIwMTY3Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/\",\"name\":\"Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODY3NyM0MzIwMjkxIzIwMTY3Nzc=\",\"datePublished\":\"2021-07-29T11:36:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODY3NyM0MzIwMjkxIzIwMTY3Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODY3NyM0MzIwMjkxIzIwMTY3Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results - Market Newsdesk","og_description":"Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET HOUSTON, July 29, 2021 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematologic cancers, today announced that the Company will host a conference call and live audio webcast on\u00a0Thursday, August 5, 2021, at 10:00 a.m. ET, to discuss its corporate and financial results for the second quarter and year-to-date 2021. Conference Call Information Interested participants and investors may access the conference call by dialing either: (833) 423-0481 (U.S.) (918) 922-2375 (international) Conference ID: 8985036 An audio webcast will be accessible via the Investors Events and Presentations section &hellip; Continue reading \"Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T11:36:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODY3NyM0MzIwMjkxIzIwMTY3Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results","datePublished":"2021-07-29T11:36:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/"},"wordCount":355,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODY3NyM0MzIwMjkxIzIwMTY3Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/","name":"Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODY3NyM0MzIwMjkxIzIwMTY3Nzc=","datePublished":"2021-07-29T11:36:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODY3NyM0MzIwMjkxIzIwMTY3Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODY3NyM0MzIwMjkxIzIwMTY3Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-report-second-quarter-2021-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=519778"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519778\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=519778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=519778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=519778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}